Humans are cumulatively exposed to acetaldehyde from various sources including alcoholic beverages, tobacco smoke, foods and beverages. The genetic-epidemiologic and biochemical evidence in ALDH2-deficient humans provides strong evidence for the causal relationship between acetaldehyde-exposure due to alcohol consumption and cancer of the upper digestive tract. The risk assessment has so far relied on thresholds based on animal toxicology with lower one-sided confidence limit of the benchmark dose values (BMDL) typically ranging between 11 and 63 mg/kg bodyweight (bw)/day dependent on species and endpoint. The animal data is problematic for regulatory toxicology for various reasons (lack in study quality, problems in animal models and appropriateness of endpoints -especially cancer -for transfer to humans). In this study, data from genetic epidemiologic and biochemical studies are reviewed. The increase in the daily exposure dose to acetaldehyde in alcohol-consuming ALDH2-deficients vs. ALDH2-actives was about twofold. The acetaldehyde increase due to ALDH2 inactivity was calculated to be 6.7 mg/kg bw/day for heavy drinkers, which is associated with odds ratios of up to 7 for head and neck as well as oesophageal cancer. Previous animal toxicology based risk assessments may have underestimated the risk of acetaldehyde. Risk assessments of acetaldehyde need to be revised using this updated evidence.
Introduction
Acetaldehyde (ethanal) is a compound to which humans are regularly exposed from multiple sources such as foods, beverages, cigarettes and the environment (Cavalcante et al., 2005; Feron et al., 1991; Homann et al., 1997; Lachenmeier et al., 2009b; Lachenmeier and Sohnius, 2008; Nazaroff and Singer, 2004; Salaspuro, 2009a Salaspuro, , 2009b Uebelacker and Lachenmeier, 2011) . Highest exposure results from consumption of alcoholic beverages and is localized to mucosal surfaces of the upper digestive tract. This is due to the fact that after alcohol intake some ethanol is metabolized locally by oral microbes and mucosal cells to acetaldehyde. Because of the inefficient ability of mucosa and microbes to eliminate acetaldehyde, the compound accumulates in the saliva and gastric juice (Homann et al., 1997 (Homann et al., , 2001 Kurkivuori et al., 2007; Lachenmeier and Monakhova, 2011; Linderborg et al., 2011; Salaspuro, 2003; Salaspuro and Salaspuro, 2004; V€ akev€ ainen et al., 2000 , 2001a , 2001b . Furthermore, acetaldehyde is found in high concentrations in some spirits, but it is also regularly present in wine and beer (Boffetta et al., 2011; Lachenmeier and Sohnius, 2008; Linderborg et al., 2008; Paiano et al., 2014) .
A point mutation in ALDH2-gene resulting in deficient activity of the main acetaldehyde metabolizing mitochondrial enzyme (ALDH2) provides conclusive evidence for the causal relationship between local acetaldehyde exposure and upper digestive tract cancer. When drinking alcohol, the upper digestive tract mucosa of ALDH2-deficients is exposed via saliva to about 2 times and via gastric juice to 5e6 times higher acetaldehyde concentrations than in persons with active ALDH2-enzyme (Maejima et al., 2015; V€ akev€ ainen et al., 2000 , 2001b Yokoyama et al., 2016; Yokoyama et al., 2008) . Parallel to increased local acetaldehyde exposure, the risk of ALDH2-deficient alcohol drinkers for oral, pharyngeal, oesophageal and gastric cancer is many fold compared to alcohol drinking ALDH2-actives (Boccia et al., 2009; Matsuo et al., 2013; Tsai et al., 2014; Yang et al., 2010) . Moreover, the difference in cancer risk between ALDH2-deficients and ALDH2-actives increases with increasing alcohol consumption. Thus, ALDH2-deficiency provides a unique human cancer model for local acetaldehyde exposure in the upper digestive tract. Based on new geneepidemiological and geneebiochemical evidence, the International Agency for Research on Cancer (IARC) has reclassified acetaldehyde associated with the consumption of alcoholic beverages as a Group 1 human carcinogen (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012; Secretan et al., 2009) .
For the risk assessment of acetaldehyde, no human data has been available so far, so that toxicological thresholds based on animal experiments have been suggested (Lachenmeier et al., 2009b) . Some risk assessment bodies such as the German Federal Institute for Risk Assessment (BfR, 2010) or the MAK Commission (2013) have questioned the use of the available animal data for oral exposure, while other bodies such as the SCCS (2012) used them to provide quantitative risk estimates and suggest risk management actions such as implementation of limits in consumer products such as cosmetics.
ALDH2-deficiency provides an entirely new human model for the quantitative estimation of increased acetaldehyde exposure via saliva in the upper digestive tract of alcohol drinking ALDH2-deficients compared to ALDH2-actives. Point mutation in ALDH2 gene has "randomized" millions of alcohol drinkers to abnormally high acetaldehyde exposure via saliva for decades thus providing a natural model. Therefore, the intention of this article was to review the human data that has become available from genetic epidemiological and biochemical research during the last decade and discuss its relevance for risk assessment.
Methods
Data on genetic epidemiological and genetic biochemical studies regarding the connection between aldehyde dehydrogenase 2 (ALDH2)-polymorphism, alcohol consumption, upper digestive tract cancer and salivary acetaldehyde concentrations in the presence of ethanol were obtained by a computer-assisted literature search. Searches were carried out in the PubMed database (U.S. National Library of Medicine, Bethesda, MD). We specifically aimed to identify studies that specified several dose groups of alcohol intake and compared ALDH2 active with ALDH2 deficient individuals, and hence might provide evidence of a clear doseresponse effect.
Results
Three studies were identified that reported about the frequency of the ALDH2 polymorphism among oesophageal cancer and head and neck cancer cases and controls according to two variant ALDH2 genotypes [*1*2(deficient) and *1*1(active)] with similar levels of alcohol intake thus providing dose-response data (Table 1) : one meta-analysis and one study on head and neck cancer (Boccia et al., 2009; Tsai et al., 2014) and one meta-analysis on oesophageal cancer (Yang et al., 2010) . The data were dichotomized according to the drinking status of the original studies.
For the estimation of local acetaldehyde exposure via saliva in different levels of alcohol intake five studies reporting in vivo salivary acetaldehyde levels in ALDH2 deficients vs. ALDH2 actives after alcohol intake were identified (Maejima et al., 2015; V€ akev€ ainen et al., 2000 , 2001b Yokoyama et al., 2016; Yokoyama et al., 2008) . The main characteristics of these studies are presented in Table 2 .
Mean blood and salivary acetaldehyde levels of ALDH2 actives and deficients after alcohol intake were averaged from the data presented in each study. In Table 3 , salivary acetaldehyde levels represent sampling time points when ethanol had been evenly distributed to the whole-body water including saliva after alcohol intake. In three studies the areas under the curve (AUCs) of acetaldehyde exposure via saliva during the follow up ranging from 2 to 4 h was either reported or could be calculated. Thereafter differences in salivary acetaldehyde exposure of ALDH2 actives and deficients were calculated. The average difference was estimated to be 2.0fold at the sampling time point (5 studies) and according to AUCs 2.2fold (3 studies) for the deficients vs the actives (Table 3 ). The average of 2.1fold was selected for further calculations in Tables 4 and 5 .
For the estimation of exposure of the upper digestive tract mucosa to acetaldehyde in mg/kg bodyweight (bw)/day, median unstimulated saliva flow rate was assumed to be 0.5 ml/min (Fenoll-Palomares et al., 2004) . Mean alcohol consumption of moderate drinkers was assumed to be 3 drinks/day corresponding to about 4.5 h exposure via saliva (141 ml saliva) to acetaldehyde ( Table 4 ). The mean alcohol consumption of heavy drinkers and corresponding exposure to salivary acetaldehyde was assumed to be 7 drinks (330 ml saliva) per day ( Table 4 ). The additional acetaldehyde exposure for ALDH2 deficient compared to ALDH2 active persons was determined by multiplying the exposure of ALDH2 actives by 2.1 as indicated in Table 3 . Table 5 compares the acetaldehyde daily dose increase with the odds ratios for the cancer types. It can be deduced that for heavy drinkers odds ratios ranging from 4 to 7 are associated with acetaldehyde dose increases of 6.7 mg/kg bw/day. Finally, Table 6 summarizes toxicological thresholds for acetaldehyde from various literature sources. It can be seen that thresholds based on animal experiments are generally above 10 mg/ kg bw/day. Thresholds based on human epidemiological data are not yet available and the study data shown in Tables 5 and 6 did not allow for a dose-response-modelling as none of the study provided absolute or extra risk data. Nevertheless, the very low acetaldehyde doses (6.7 mg/kg bw/day) associated with significantly increased odds ratios for cancer, provide plausibility that the human threshold could lie considerably lower than 0.1 mg/kg bw/day.
Discussion
ALDH2-deficiency resulting from a single point mutation in ALDH2-gene is a health risk that passes in frequency familiar hypercholesterolemia (FH). The incidence of FH is 1:500 but that of ALDH2-deficiency 1:13. ALDH2-gene mutation took place in South China over 2000 years ago, and today its carrier frequency is close to 600 million people of East-Asian descent (Brooks et al., 2009; Li et al., 2009; Luo et al., 2009) . Deficient activity of ALDH2-enzyme results in decreased ability to detoxify acetaldehyde locally formed from ethanol and thus provides a unique human model for increased exposure of upper digestive tract mucosa to acetaldehyde via saliva after drinking of alcohol (Helminen et al., 2013; Maejima et al., 2015; V€ akev€ ainen et al., 2000 , 2001b Yokoyama et al., 2016; Yokoyama et al., 2008) . With increased exposure to salivary acetaldehyde, oral, pharyngeal and oesophageal cancer risks of alcohol drinking ALDH2 deficients are many folds compared to ALDH2 active drinkers, and the higher their alcohol consumption has been (Boccia et al., 2009; Tsai et al., 2014; Yang et al., 2010) .
Acetaldehyde is a cytotoxic, genotoxic and mutagenic compound and carcinogenic in experimental animals (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012; Seitz and Stickel, 2010) . In conjunction with the consumption of alcoholic beverages, acetaldehyde has been reclassified as carcinogenic to humans (Group 1) (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012; Secretan et al., 2009 ). The new classification concerns both the acetaldehyde formed from ethanol by local microbial and mucosal oxidation as well as when present in alcoholic beverages.
Due to its aldehyde group, acetaldehyde is very reactive and easily binds to various tissue components, including DNA, and forms carcinogenic adducts both in vitro and in vivo. Increasing concentrations of acetaldehyde ranging from 25 to 500 mM in the presence of DNA and polyamines, produce an exponential increase of mutagenic 1,N 2 -propanodeoxyguanosine adducts (Theruvathu et al., 2005) . Polyamine synthesis is tightly related to cellular proliferation, with the highest levels being found in rapidly dividing cells. This is characteristic for the regenerating upper digestive tract mucosa (Tabor and Tabor, 1984) . In human volunteers, low doses of alcohol have been shown to produce a dose-dependent increase in acetaldehyde-DNA adducts (N 2 -ethylidene-dGuo) in the oral cavity (Balbo et al., 2012) . Corresponding doses of alcohol have been shown to result in 18.7e143.4 mM acetaldehyde levels in saliva (Homann et al., 1997) . In contrast to Balbo et al. (2012) N 2 -ethylidene-dGuo adducts were not observed in peripheral blood white cells of human volunteers 48 h after exposure to 150 ml of vodka (Singh et al., 2012) . This discrepancy, however, is not unexpected, since only very low acetaldehyde concentrations are found in hepatic venous blood of intoxicated non-alcoholic male Caucasians (Nuutinen et al., 1984) and acetaldehyde levels are undetectable (<2 mM) in the peripheral blood (Table 3) .
After alcohol intake, several times higher concentrations of acetaldehyde are found in the saliva than in the blood (Table 3 ) (V€ akev€ ainen et al., 2000 , 2001b Yokoyama et al., 2008) . This is due to the fact that parotid glands, oral microbes and upper digestive tract mucosal cells are able to oxidize ethanol to acetaldehyde, but are not sufficiently capable for its detoxification unlike the liver. The high local exposure to acetaldehyde formed from ingested ethanol is in line with epidemiological findings. In alcohol drinking ALDH2-deficient individuals compared to ALDH2-actives, the incidence of those cancers exposed to acetaldehyde derived locally from cellular and microbial oxidation of ethanol is increased, especially of the upper digestive tract including stomach (Boccia et al., 2009; Roerecke et al., 2015; Yang et al., 2010; Hidaka et al., 2014; Wang et al., 2014; Matsuo et al., 2013) . On the contrary, the incidence of cancers of organs not covered with microbes appears not to be increased in alcohol drinking ALDH2-deficients compared to ALDH2-actives e.g. cancers of breast, kidney, liver or the evidence is contradictory as in the case of pancreas (Kanda et al., 2009; Kawase et al., 2009; Miyasaka et al., 2005; Yokoyama et al., 1998; Zhou et al., 2012) .
Although only acetaldehyde associated with alcohol consumption has been shown to be carcinogenic to humans, any genotoxic, mutagenic and carcinogenic compound irrespective of its origin should concern equal regulatory rules and restrictions (EFSA, 2005) . This is particularly true with acetaldehyde that is easily water and lipid soluble and thus passes readily through cell membranes. Acetaldehyde probably is one of the most prevalent human carcinogens. It is present, sometimes in high concentrations, in several alcoholic beverages. It is accumulating in the digestive tract including saliva, gastric juice and colonic contents due to its local formation from ethanol by mucosal cells and microbes (Salaspuro, 2003 (Salaspuro, , 2009a . Tobacco smoking may lead to considerable exposure, due to the presence of acetaldehyde in the smoke (Baumung et al., 2016; Cunningham et al., 2011; Salaspuro and Salaspuro, 2004; Xie et al., 2012) , which dissolves into the saliva and is by that means distributed to the mucosal surfaces of the whole upper digestive tract. Moreover, it has also been detected in smoking cessation products such as electronic cigarettes (Hahn et al., 2014) . Fermented foods such as yoghurt may naturally contain acetaldehyde, and the substance may also be added to certain foods as a flavouring compound, especially for its capability to improve orange flavour (Lachenmeier et al., 2010; Uebelacker and Lachenmeier, 2011) . Acetaldehyde has also been detected in certain cosmetics (Lachenmeier et al., 2009a; SCCNFP, 2004) , as well as in household and urban air (Bakeas et al., 2003; Nazaroff and Singer, 2004) .
Despite its ubiquitous presence and the expected daily lifetime intake of humans in industrial societies, the toxicological assessment of acetaldehyde has not reached much attention and there are no regulatory limits for any of the mentioned products (the only regulation in the EU for acetaldehyde restricts its migration from packaging materials such as PET into foods to a certain level Table 1 Studies reporting the frequency of the ALDH2 polymorphism among oesophageal cancer (Yang et al., 2010) and head and neck cancer (Boccia et al., 2009; Tsai et al., 2014) (Choodum et al., 2007; Mutsuga et al., 2006) ). The lack of regulation can be probably explained historically because acetaldehyde received the 'generally recognized as safe' (GRAS) status by the Flavor and Extract Manufacturers Association (FEMA) in 1965 (Hall and Oser, 1965) . This status was corroborated by the Joint FAO/ WHO Expert Committee on Food Additives (JECFA) in 1998 (JECFA, 1998). However, in the case of acetaldehyde, the application of JECFA's decision tree for flavouring substances includes a crucial misconception with regard to acetaldehyde's metabolism (WHO, 2000) . Because of the lack of low K m aldehyde dehydrogenase enzymes in the oral mucosa, acetaldehyde accumulates in the presence of ethanol in the saliva and is not metabolized into innocuous products in the oral cavity (Dong et al., 1996) . Via saliva, carcinogenic acetaldehyde is distributed to the mucosal surfaces of the mouth, oesophagus and stomach. As a matter of fact, a large body of evidence has been acquired over the last decade that may question these early risk assessments. Specifically, the evidence for carcinogenic and genotoxic effects of acetaldehyde has been improved leading the International Agency for Research on Cancer to assign acetaldehyde into group 2B as being 'possibly carcinogenic to humans ' in 1987 ' in (IARC, 1987 ; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1999), while it was upgraded in association with alcohol consumption into group 1 (i.e., the highest level of evidence) in 2009 (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012; Secretan et al., 2009 ).
The differences in the order of magnitude of toxicological threshold values for acetaldehyde between animal experiments and human epidemiology are not unexpected. In this study, human data was restricted to upper digestive tract cancers i.e. on the local carcinogenic potential of acetaldehyde. With regard to acetaldehyde, the use of human data has several advantages as compared to animal data. In animal model studies with rodents, acetaldehyde has been administered without the presence of ethanol, but only acetaldehyde associated with alcoholic beverages has been classified as human group 1 carcinogen. Gastrointestinal tract mucosa of rodents is known to be able to metabolize both ethanol and acetaldehyde (Koivisto and Salaspuro, 1996; Pronko et al., 2002) . Without the competing presence of ethanol, some of the acetaldehyde given to rodents in drinking water is metabolized by mucosal cells and the rest of it completely by the liver to acetate (Matysiak-Budnik et al., 1996) . Thus, the first-pass metabolism of acetaldehyde mediated mostly by the liver totally eliminates possible systemic effects of acetaldehyde via blood circulation to other organs.
The BfR (2010) remarked in their criticism of the dose-response relationship in the oral lifetime rat feeding study of Soffritti et al. (2002) that the statistical power has not been sufficient for the relevant endpoints to evaluate the acetaldehyde carcinogenicity such as tumours of the oral cavity and oesophagus. Therefore, they expected the toxicological threshold to be below the first dose (i.e. 5 mg/kg bw/day) or lower. In light of the sensitivity of the animal tests alone, the lower results in humans appear plausible.
Using a unique genetic human model for increased local acetaldehyde exposure of the upper digestive tract has major advantages over animal data. Nature has randomized millions of alcohol drinking persons to different quantities of acetaldehyde exposure. This type of human model based on a single point mutation is not available for any other of the 119 IARC group 1 carcinogens. The model makes it possible to minimize the effect of important confounding factors such as smoking, diet, oral hygiene, HPV, different beverages, drinking habits, BMI and under reporting that are days before the experiments with or without slow-release L-cysteine. L-cysteine binds effectively to acetaldehyde and inactivates its reactive aldehyde group. d Excluded, since only local acetaldehyde formation in the mouth was studied. No ethanol was delivered to saliva via systemic blood circulation.
Table 3
Mean blood and salivary acetaldehyde levels of ALDH2-actives (ALDH2þ) compared to ALDH2-deficients (ALDH2-) after oral intake of alcohol. Difference in salivary acetaldehyde exposure was calculated in two ways: 1. Salivary acetaldehyde concentration at sampling time point of ALDH2-deficients was divided by that of ALDH2-positives. 2. Area under the curve (AUC) of the salivary acetaldehyde curves during the follow-up period (2e4 h) of ALDH2-deficients was divided by that of ALDH2-positives. -Levels in saliva are several times higher than in blood -In ALDH2-deficients levels are 1.5e2.3fold higher than in ALDH2-actives Salivary ethanol levels range from very low 2e4 mM to very high 61 mM
The difference in salivary acetaldehyde exposure between ALDH2-actives and edeficients appears to be equal when averaged either from single sampling time points or from AUCs. Mean 2.1 was selected for further calculations in Tables 4 and 5 a Acetaldehyde levels of sterile parotid gland saliva were undetectable in three ALDH2-actives and 75.0, 21.8 and 3.9 mM in three ALDH2-deficients. Suggests that additional salivary acetaldehyde in ALDH2-deficients is derived from salivary glands. b 4-Methylpyrazole (ADH inhibitor) treatment inhibited totally the increase in salivary acetaldehyde among ALDH2-deficients but had no effect on salivary acetaldehyde in ALDH2-actives. Suggests that additional salivary acetaldehyde in ALDH2-deficients is derived from salivary glands. c Alcohol was infused intragastrically that may result in lower salivary acetaldehyde levels. Nevertheless, differences in salivary acetaldehyde levels between ALDH2-actives and -deficients were comparable to those found in other studies. d In line with earlier findings, higher salivary ethanol levels result in higher salivary acetaldehyde levels. This is caused by the kinetics of different microbial alcohol dehydrogenase enzymes. e The significance of differences in salivary acetaldehyde levels between ALDH2-actives and edeficients. generally hampering most epidemiological studies focusing on alcohol and cancer. Among ALDH2-deficient and ALDH2-active individuals these important confounding factors can be assumed to be more or less evenly distributed.
Conclusions
Our data based on human epidemiology corroborate the findings of previous studies based on animal toxicology (see overview in Table 6 ) in the fashion that these studies at least have not overestimated the risk of acetaldehyde. The unique human geneeepidemiological and geneebiochemical evidence, even if limited by some uncertainty, points in the direction that the risk of acetaldehyde has been underestimated rather than overestimated.
In light of this evidence, it is commendable that the European Commission has recently stated that they will raise the issue of acetaldehyde with the competent authorities of the member states and, if appropriate, the European Food Safety Authority (EFSA) will be requested to assess the risk for human health related to the presence of acetaldehyde in food as process contaminant or as natural flavour (Borg, 2014) . We basically agree with this assessment of the commission and clearly believe in a considerable appropriateness of an EFSA assessment, however, we think that the addition of acetaldehyde as artificial flavour to foods, which still is a common and legal practice, might specifically require scrutiny. It must be noted that the German Federal Institute for Risk Assessment remarked in 2010 that the safety of acetaldehyde when used as flavouring substance cannot be finally evaluated (BfR, 2010) . This raises the question why potentially unsafe flavour additives may be used in foods prior to the proof of their safety by adequate studies conducted by the industry. There is currently no evidence that acetaldehyde present in 'non-alcoholic' foods and beverages is more safe than acetaldehyde associated with the use of alcoholic beverages. Tables 2e4.  b The results indicate that fast ADH enzyme does not correlate with increased head and neck cancer risk among ALDH2-deficients. This is in accordance with no effect of fast ADH on salivary acetaldehyde levels in the presence of ethanol in ALDH2-deficient alcoholics (Yokoyama et al., 2016) .
Table 4
Calculation of the exposure of upper digestive tract mucosa to acetaldehyde via saliva in ALDH2-actives and -deficients.
Acetaldehyde exposure via saliva Never/rare drinkers (see Table 1) Moderate drinkers (see Table 1 ) (3 drinks ¼ 33 g/day)
Heavy drinkers (see Table 1 f a Acetaldehyde exposure time is 1.5 h/drink (1 drink ¼ 11 g ethanol) based on the normal elimination rate of ethanol (7 g/h) (Cederbaum, 2012). b Unstimulated saliva flow rate is assumed to be 0.5 ml/min (Fenoll-Palomares et al., 2004) . c 1.1 mg/l is calculated as indicated in Table 3 . d Mean weight ¼ 60 kg. e x 2.1 (Table 3) . f ALDH2 def. e ALDH2 act.
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